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ÖZET
Amaç:  Bu  çalışmadaki  amacımız  kanayan  veya  daha 
önce kanamış olan gastrik varislerde syanoacrilat ve lipi-
odol karışımının hemostazdaki etkisini saptamaktır.
Gereç  ve  yöntem:  2003-2010  tarihleri  arasında  aktif 
kanayan veya kanama bulgusu olan ve iki hafta içinde 
endoskopi  ünitesine  kabul  edilen  15  hasta  retrospektif 
olarak değerlendirildi. Syanoacrilat ve lipiodol karışımını 
gastrik varisli hastalarda başarılı şekilde uyguladık ve tüm 
hastalara endoskopik işlem, varisler başarılı şekilde teda-
vi edilene kadar aylık peryotlarla tekrarlandı.
Bulgular: Syanoacrilatlı skleroterapi ile aktif kanayan 9 
hastada başlangıçta hemostaz sağlandı. Tekrar kanama, 
1 hastada 24 saat sonra diğer hastada 2 ay sonra görüldü 
(2/15, %13,3). Takip süresince gastrik varis eradikasyonu 
13 hastada (%86,7) başarıldı. Bir hasta tekrar kanama-
dan  opere  edildi  diğer  hasta  karaciğer  yetmezliğinden 
öldü. Gastrik varis eradikasyonundan sonra 5 yıllık yaşam 
14/15 (%93,3) idi.
Sonuç: Bu çalışmada aktif kanayan ve kanama işareti 
olan gastrik varisli hastalarda syanoacrilat lipiodol kombi-
nasyonu ile skleroterapinin etkili tedavisi gösterildi. 
Anahtar kelimeler: Endoskopik skleroterapi, siyanoakri-
lat, lipiodol, gastrik varis
ABSTRACT
Objectives: The aim of this study was to determine ef-
fect of N-Butyl-2 Cyanoacrylate (CA) and lipiodol mixture 
injection for hemostasis of bleeding gastric varices or le-
sions, which had bled from gastric varices.
Materials  and  methods  Fifteen  patients  with  active 
bleeding or bleeding findings within two weeks who ad-
mitted to endoscopic unit of a low volume medical center 
were evaluated retrospectively between 2003 and 2010. 
We carried out endoscopic sclerotherapy successfully to 
gastric varices with combination of N-Butyl-2 Cyanoacry-
late and Lipiodol (CALM), with dramatical success over 
months after sessions of sclerotherapy for each patient.
Results:  Sclerotherapy  with  cyanoacrylate  achieved 
hemostasis in all actively bleeding nine patients initially. 
Rebleeding occurred in a patient 24 hours later and in 
another patient two months later (2/15, 13.3%). Eradica-
tion of gastric varices was achived in 13 (86.7 %) patients 
during follow-up. One patient was operated because of 
rebleeding. One patient died as a result of liver failure. 
Five-year survival rate of the patients after eradication of 
gastric varices was 14/15 (93.3%).
Conclution: This study indicated that sclerotherapy with 
N-Butyl-2 Cyanoacrylate and lipiodol mixture is an effec-
tive treatment method for patients with bleeding gastric 
varices and also for eradication of gastric varices.
Key  words:  Endoscopic  sclerotherapy,  cyanoacrylate, 
Lipiodol, gastric varices
INTRODUCTION
Gastric  varices  (GV)  are  the  hemodynamic  re-
sult in patients with portal hypertension. Approxi-
mately  20%  of  patients  with  portal  hypertension 
suffer from GV.1,2 GV associated with esophageal 
varices named as gastroesophageal varices (GOV) 
are listed as: type 1 (GOV1), along the lesser curve, 
or type 2 (GOV2), along the fundus and the ones 
present in isolated places named as isolated gastric Y. Tuna et al. Cyanoacrylate in bleeding gastric varices 388
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varices (IGV), are listed as: in the fundus IGV 1, 
in the ectopic sites of stomach or in the first part of 
the duodenum IGV2.1 GV bleeding is an important 
lethal complication of cirrhosis, and it’s secondary 
to portal hypertension.3 Hemorrhage caused by GV 
is usually severe and hemostatic control is reported 
to be more difficult, compared with esophageal va-
riceal bleeding. The high early mortality rate of va-
riceal bleeding has been prime motivation for treat-
ment of patients. Incidence rate of bleeding in portal 
hypertension and cirhosis has been reported as 55 
to 78%. Patients who bleed from gastric varices ap-
pear to have high mortality.1
Several methods have been tried in order to treat 
GV bleeding with variable success.4-7 Endoscopic 
sclerotherapy is an effective theurapeutic modality 
of fundal varices bleeding. Many sclerosants have 
been used for variceal sclerotherapy. Intravariceal 
injection  of  cyanoacrylate  (CA)  produced  at  ini-
tial hemostasis has a rate of 87% to 100%. After 
the initial treatment subsequent sclerotherapy ses-
sions have been required to achieve oblitaration of 
varices.8-10 Oblitaration effect of CA is excellent on 
IGV1. However this effect in patients without ac-
tive bleeding is controversial.11 Effective variceal 
oblitaration is determined, but early rebleeding rate 
was very high.12
The aim of this study was to determine the ef-
fect of N-Butyl-2 Cyanoacrylate (Histoacryl, Braun 
Dexan)  and  lipiodol  mixture  (CALM)  injection 
for hemostasis of actively bleeding GV and lesion 
which had bled from GV.
MATERIALS AND METHODS
The study included 15 patients who were admitted 
for emergency treatment of gastric fundal variceal 
bleeding or lesions which had bled from gastric fun-
dal variceal, between 2003 and 2010. The patients 
were evaluated retrospectively.
Inclusion Criteria
The inclusion criteria were active fundal gastric va-
riceal hemorrhage, a recent history of bleeding at-
tributed to fundal gastric varices. Active bleeding 
was defined as observed spurting or oozing of blood 
from a fundal varix or the presence of an overlying 
clot and absence of any other source of bleeding, 
such as esophageal varix, portal hypertensive gas-
tropathy, or gastric antral vascular ectasia. Eleven 
patients  presented  with  acute  GV  bleeding.  Past 
bleeding: Patients with large GV,with absent esoph-
ageal varices, who had bled in the past from GV 
were included in this category. Four patients pre-
sented with past bleeding. 
All patients were requested to sign an informed 
consent before endoscopic procedure.
Exclusion Criteria 
Patients who were undergoing endoscopic sclero-
therapy or banding for esophageal varices, pregnan-
cy, inability to give informed consent for the proce-
dure, multi-organ failure, patients with hepatorenal 
syndrome or hepatic encephalopathy and patients 
not giving informed consent for endoscopic proce-
dures were excluded.
Gastric varices
The gastric varices were classified according to their 
location using the Sarin classification: Varices in the 
esophagus and lesser curvature (GOV1); varices in 
the esophagus and gastric fundus (GOV2); varices 
in the fundus only (IGV1), or at ectopic sites such 
as the body, antrum, or duodenum (IGV2). Further-
more, varices were classified based on their size as 
F1 (mild, linear, tortuous), F2 (moderate, nodular) 
or F3 (severe, tumorlike). In case of active bleeding, 
the hemorrhage was described as either oozing or 
spurting. The presence of a clot or a tear on a varix 
with blood in the stomach and without any evidence 
of another bleeding source was also considered a 
sign of active variceal bleeding.
Endoscopic and medical treatment
In our endoscopy unit, a mixture of N-Butyl-2 Cy-
anoacrylate (Histoacryl,Braun Dexan) and Lipiodol 
(CALM) 0,5 mL to 0,5 mL ratio was applied using 
a front-view type endoscope (Olympus, CV 240, 
Tokyo, Japan) in the retroflexed position. N-butyl-2
-cyanoacrylate and lipiodol are mixed in equal pro-
portions before use and are injected into the varices 
using a 23 gauge disposable sclerotherapy needle 
catheter  (Boston  Scientific, Tokyo,  Japan)  that  is 
passed through the biopsy canal. Before adminis-
tering the mixture, the needles are flushed with just 
enough isotonic sodium chloride solution for a few 
drops to appear at the tip. The mixture is then ap-
plied in different quantities as needed to achieve he-Y. Tuna et al. Cyanoacrylate in bleeding gastric varices 389
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mostasis, after which the canal is again flushed with 
the same amount of sodium chloride solution that 
was used before. To decrease the risk of a variceal 
tear the tip of the needle is withdrawn before the 
glue sets, after which the catheter is held in place for 
3–4 s to prevent leakage of the mixture from the va-
rices. CALM was tried to be injected intravaricely 
without extravasation of solution which may give 
damage to the endoscopes. 1 mL of CALM was per-
formed for each session of the GV sclerotherapy.
We observed and felt when the needle is pene-
trating the variceal wall. We repeated sclerotherapy 
with same volume of CALM if the active bleeding 
was persistant. If GV remained soft and not obliter-
ated enough, sclerotherapy procedure was carried 
on for eradication of large varices once a week until 
obtaining the optimum theurapeutic effect accord-
ing to the endoscopic examination. CALM was tried 
to be injected intravaricely without extravasation of 
solution which may give damage to the endoscopes. 
1 mL of CALM was performed for each session of 
the GV sclerotherapy. We observed and felt when 
the needle is penetrating the variceal wall. We re-
peated sclerotherapy with same volume of CALM 
if the active bleeding was persistant. Patients are re-
evaluated 4-6 weeks after the index endoscopy, and 
variceal obliteration is checked by probing with a 
catheter tip. The glue injection is repeated every 4-6 
weeks until obliteration is achieved, after which a 
follow-up endoscopy is performed at 3-month in-
tervals.
For  all  patients  who  presented  with  gastric 
bleeding, appropriate fluid resuscitation, prophylac-
tic antibiotics, proton pump inhibitor and somatosta-
tin infusion were initiated before each procedure. 
All of the acute bleeders received the vasoactive 
drug somatostatin infusion for 72 hours after admis-
sion. We followed up patients for a long time to de-
termine outcome, variables were initial hemostasis 
rate, early and late rebleeding rate, recurrence rate 
of GV mortality and sclerotherapy complications.
Statistical analysis
All data were expressed as mean ± SD or percent-
age. Statistical significance was determined using 
the chisquare test and significance was taken at P < 
0.05. The statistical analysis was performed using 
the SPSS package (version 16.0 J; SPSS Inc., Chi-
cago, Illinois, USA). 
RESULTS
A  total  of  fifteen  patients  (mean  age:  51  ±  16.2 
years; range 19-75 years; 10 males-5 females) with 
GV  underwent  endoscopic  sclerotherapy with  N-
butyl-2-cyanoacrylate  (Histoacryl,  Braun  Dexan) 
and  lipiodol  mixture  (CALM)  injection  between 
2003 to 2010. The etiology of portal hypertension 
patients was liver cirhosis (11/15, 73%) and non-
cirhotic portal hypertension (NCPH) (4/15, 27%). 
Cirrhosis was HBV related in five patients, alcohol 
related in three patients, and with unknown etiology 
in three patients. NCPH causes of GV included por-
tal vein trombosis (2/4) and splenic vein trombosis 
(2/4). The number of Child-Pugh A, B, and C cases 
according to severity of liver disease were 4, 6, and 
1, respectively.
All of the patients had gastric varices (10 IGV 
1, 4 GOV 1, 1 GOV 2). The majority of GV were 
IGV 1 (10/15, 66.7 %). The mean number of up-
per gastrointestinal bleeding was 2.6 ± 2.4 (range 
0-10) at the presentation. Nine patients had active 
GV bleeding during endoscopic examination. Five 
patients had achieved eradication of esophageal va-
rices before sclerotherapy.
Actively gastric varice bleeding was observed 
in most of the patients during endoscopic examina-
tion  (9/15,  60%).  CALM  injection  sclerotherapy 
achieved  hemostasis  in  all  of  the  actively  bleed-
ing patients during initial endoscopic examination 
(9/9). Only one patient had rebleeding within 24 
hours. Eradication of gastric varices was achieved 
in 13 (86,6%) patients. A mean number of 1.7 ± 1.03 
(range, 1-4) sessions was required to eradicate the 
gastric varices; 9 patients required 1 session; 2 pa-
tients required 2 session; three patients required 3 
session, 1 patient required four session (range 1-4). 
The volume of prepared CALM required to control 
the bleeding gastric varices ranged from 1 to 4 ml 
with a mean total volume of 1,7 ± 1.03 mL of CA 
was used. Number os sessions of endoscopic scle-
rotherapy with CA was 1.7 ± 1.03 (range, 1-4), re-
sulting obliteration of GV in all patients. Only six 
patients (6/15, 40%) had more than 2 sessions of 
sclerotherapy.
Recurrence  of  gastric  varices  was  observed 
in two patients after 6 months from sclerotherapy 
(2/15). An early and a late rebleeding was deter-
mined in two patients (2/15, 13,3%). Early rebleed-Y. Tuna et al. Cyanoacrylate in bleeding gastric varices 390
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ing occurred 24 hours artery sclerotherapy. This pa-
tient was operated because of uncontrolled rebleed-
ing. One patient died because of liver failure during 
follow-up (1/15, 6.6%). We observed one damage 
case of endoscope because of CA leakage. There 
were  no  major  systemic  and  local  complications 
such as cerebral stroke, pulmonary embolism, por-
tal vein embolism and splenic infarction. None had 
remarkable changes in blood tests and vital signs 
after sclerotherapy.
Four patients with NCPH had no signicicant 
differences  in  age,  sex,  number  of  bleeding  epi-
sodes, number of sessions required for erredication 
of  gastric  varices,  complications,  and  amount  of 
CALM used.
Table 1. Patients demographics and clinical characteris-
tics
Number of patients 15
Male / Female 10 / 5
Mean age 51 ± 16.2 (19-75)
IGV 1 10 / 15 (66.7 %)
GOV 1 4 / 15 (26.7 %)
GOV 2 1 / 15 (6.6 %)
Active bleeding  9 / 15 (60 %)
Recent bleeding 6 / 15 (40%)
Child-Pugh A / B / C 4 / 6 / 1
IGV:  isolated  gastric  varices,  GOV:  Gastroesophageal 
varices
Table 2. Etiology of portal hipertension
Cirrhosis 11 / 15 (73%)
HBV 5 / 11
Alcohol 3 / 11
Unknown 3 / 11
NCPH 4 / 15 (27 %)
Portal vein trombosis 2 / 4
Splenic vein trombosis 2 / 4
NCPH: Noncirrhotic Portal Hypertension
HBV: Hepatitis B viruses
Table 3. Hemostasis for gastric varices
Mean volume of CA required 1,7±1.03 mL
Mean sessions of sclerotherapy 1.7
Hemostasis rate for active bleeding of GV 9/9 (100%)
Recurrent bleeding rate 2/15 (13%)
Early rebleeding rate 1/15 (6.6%)
Late rebleeding rate 1/15 (6.6%)
Recurrence of GV 2/15 (13.3%)
Bleeding Mortality (0/15)
CA: Cyanoacrylate, GV: Gastric varices
DISCUSSION
In the present study, we have documented succesful 
eradication of either bleeding or non-bleeding gas-
tric varices with CALM. CALM is a cheap and safe 
method for gastric varice eradication.
The incidence of gastric variceal bleeding is lower 
than esophageal varices. However, bleeding from 
GV results in more severe hemorrhage and higher 
mortality because of large draining veins and abun-
dant blood flow.1 Efficacy of CA sclerotherapy for 
emergency and elective IGV 1 bleeding is excellent. 
Cyanoacrylate sclerotherapy is first line treatment of 
acute IGV1 bleeding7 however use of CA in patients 
without acute bleeding is controversial, because re-
bleeding rate was relatively high.11,13 Most rebleed-
ing  occurred  in  first  year  after  CA  sclerotherapy 
during 10 year follow-up.14
Cyanoacrylate  is  a  hydrophilic  polymer  and 
spontaneously  polimerized  in  water.  Because  of 
this property, it has been used to obliterate actively 
bleeding gastric varices.12,15,16 We achieved hemo-
stasis  in  actively  bleeding  patients  during  initial 
endoscopic examination with injection of CALM 
solution (9/9). This property of CALM was very 
important for obliteration of gastric varices imme-
diately in emergency conditions. Only one patient 
had rebleeding within 24 hours (1/15,6.6%) and was 
operated. One patient with initial hemostasis had re-
current rebleeding after 3 months and died because 
of liver failure during follow up.
At this study, CALM has no adverse effects 
on liver function according to Child-Pugh classifi-
cation. A previous study indicated that N-Butyl-2 
Cyanoacrylate injection had little influence on the 
survival of patient with advanced liver failure.10,17,18 Y. Tuna et al. Cyanoacrylate in bleeding gastric varices 391
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One patient died from liver failure during follow 
up.
At this study most of the patients applied in 
emergency conditions because of active bleeding. 
We had demonstrated successful initial hemostasis 
of active gastric varices bleeding. Early hemostasis 
rate in actively bleeding patients was 88.8% (8/9) 
and five-year survival rate of patients with cirhosis 
was 90.9% (10/11). Rare but serious complications 
like  cerebral  stroke,  pulmonary  embolism,  portal 
vein embolism and splenic infarction11 of endoscop-
ic sclerotherapy was not observed in our cases and 
rebleeding rate is lower ( 2/15, 13.3%) than previ-
ous reports (30%).12,13,19,20 Two patients had recurrent 
gastric varices and thirteen patients had a clinical 
course of more than 4 years without any recurrence. 
Extravasation of solution, which gave damage to 
the endoscope, was occurred in a case.
There were some limitations to our study. The 
first is the small number of patients in a retrospec-
tive manner. Large number of patients with gastric 
varices bleeding may be necessary to confirm our 
results. Second, a control group including a method 
other than CALM such as band ligation, alcohol 
injection would further demonstrate the efficacy of 
CALM.
In conclusion, the optimal treatment of gastric 
varices remain unclear. Nb2c-lipiodol mixture is a 
low-cost, effective and easy to use treatment. This 
study indicated that sclerotherapy with N-Butyl-2 
Cyanoacrylate and lipiodol mixture may be an ef-
fective treatment method for patients with gastric 
varice bleeding in emergent and elective conditions. 
Patients with cirrhosis and NCPH have high eradi-
cation rate of gastric varices with -Butyl-2 Cyano-
acrylate and lipiodol mixture as a sclerosing agent 
and relatively low complication rate.
REFERENCES
1. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. 
Prevalence, classification and natural history ofgastric va-
rices: a long-term follow-up study in 568 portal hyperten-
sion patients. Hepatology 1992; 16(6): 1343-9.
2.  Thakeb  F,  Salem  SA,  Abdullah  M,  el  Batanouny  M. 
Endoscopic  diagnosis  of  gastric  varices.  Endoscopy 
1994;26(3):287–9.
3. Graham DY, Smith JL. The course of patients after variceal 
hemorrhage. Gastroenterology 1981;80(4):800–9.
4. Ramond MJ, Valla D, Mosnier JF, et al. Successful endo-
scopic obliteration of gastric varices with butyl cyanoacry-
late. Hepatology 1989;10(4):488–93.
5. Gimson AE, Westaby D, Williams R. Endoscopic sclerother-
apy in the management of gastric variceal hemorrhage. J 
Hepatol 1991;13(3):274–8.
6. Soehendra N, Nam VC, Grimm H, Kempeneers I. Endoscop-
ic obliteration of large esophagogastric varices with bucry-
late. Endoscopy 1986;18(1):25–6.
7. Yoshida T, Hayashi N, Suzumi N, et al. Endoscopic liga-
tion of gastric varices using a detachable snare. Endoscopy 
1994;26(5): 502–5.
8. Huang YH, Yeh HZ, Chen GH, et al. Endoscopic treatment 
for  bleeding  gastric  varices  by  N-butyl-2-cyanoacrylate 
(Histoacryl) injection: longterm efficacy and safety. Gas-
trointest Endosc 2000;52(2):160-7.
9. Iwase H, Maeda O, Shimada M, et al. Endoscopic ablation 
with cyanoacrylate glue for isolated gastric variceal bleed-
ing. Gastrointest Endosc 2001;53(6):585-92.
10. Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A pro-
spective, randomized trial of butyl cyanoacrylate injection 
versus band ligation in the management of bleeding gastric 
varices. Hepatology 2001;33(5):1060-4.
11. Binmoeller KF. Glue for gastric varices: some sticky issues. 
Gastrointest Endosc 2000;52(2):298-301.
12. Akahoshi T, Hashizume M, Shimabukuro R, et al. Long-
term  results  of  endoscopic  Histoacryl  injection  sclero-
therapy for gastric variceal bleeding: a 10-year experience. 
Surgery 2002;131(1):176-81.
13. Sarin SK, Jain AK, Jain M, Gupta R. A randomized con-
trolled  trial  of  cyanoacrylate  versus  alcohol  injection  in 
patients with isolated fundic varices. Am J Gastroenterol 
2002; 97(4):1010–1015
14. Soehendra N, Grimm H, Nam VC, Berger B. N-butyl-2- 
cyanoacrylate: a supplement to endoscopic sclerotherapy. 
Endoscopy 1987;19(6):221–4.
15. Cheng PN, Sheu BS, Chen CY, Chang TT, Lin XZ. Splenic 
infarction after Histoacryl injection for bleeding gastric va-
rices. Gastrointest Endosc 1998;48(4):426–7.
16. Jutabha R, Jensen DM, Egan J, Machicado GA, Hirabayashi 
K. Randomized, prospective study of cyanoacrylate injec-
tion, sclerotherapy, or rubber band ligation for endoscopic 
hemostasis of bleeding canine gastric varices. Gastrointest 
Endosc 1995;41(3): 201–5. 
17. Ng WD, Chan YT, Ho KK, Kong CK. Injection sclero-
therapy  for  bleeding  esophageal  varices  in  cirrhotic  pa-
tients with hepatocellular carcinoma. Gastrointest Endosc 
1989;35(1):69–70.
18. Sung JJ, Yeo W, Suen R, et al. Injection sclerotherapy for 
variceal bleeding in patients with hepatocellular carcinoma: 
cyanoacrylate versus sodium tetradecyl sulphate. Gastroin-
test Endosc 1998;47(3):235–9.
19. Greenwald BD, Caldwell SH, Hespenheide EE, et al. N-2- 
butyl-cyanoacrylate for bleeding gastric varices: a United 
States pilot study and cost analysis. Am J Gastroenterol 
2003;98(9):1982–1988
20. Oho K, Iwao T, Sumino M, Toyonaga A, Tanikawa K. Etha-
nolamine  oleate  versus  butyl  cyanoacrylate  for  bleeding 
gastric varices: a nonrandomized study. Endoscopy 1995; 
27(5):349–54.